Loading
A phase 1/2 trial of ACP-196 in glioma & glioblastoma, run by Acerta Pharma BV, active and no longer recruiting.
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) is a phase 1/2 interventional study registered as NCT02586857 by Acerta Pharma BV, with 24 participants enrolled, started 2016-01-25 and due to reach its primary completion in 2020-06-26. Interventions recorded: ACP-196. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
24 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2020-07-29), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Assessment of Tumor Status for Overall Response Rate With Use of RANO Criteria.primary | Cohort 1 | 15 | 1 participants | - | - | link |
| Cohort 2 | 9 | 1 participants |
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares AstraZeneca, Glioma & glioblastoma and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.